Peptide Academy · Fat Loss
Educational research summary, not medical advice. Many compounds here are not approved for human use. Talk to a licensed clinician before making any health decision.
The Peptide Academy is free to read. Members also get the research protocols for Efpeglenatide, dose and vial tracking, and an AI Advisor with cited sources. Try it all free for 7 days, no card needed.
Start my free 7-day trialEfpeglenatide is a long-acting, once-weekly GLP-1 receptor agonist based on the exendin-4 scaffold (same origin as exenatide), developed by Hanmi Pharmaceuticals and licensed to Sanofi. It uses PEGylation to extend its half-life to approximately one week. The AMPLITUDE-O cardiovascular outcomes trial demonstrated significant reductions in MACE (cardiovascular death, heart attack, stroke) and kidney outcomes in patients with type 2 diabetes at high cardiovascular risk — even in patients not on background SGLT2 inhibitor therapy. This established efpeglenatide as having robust cardiorenal protective properties. While regulatory approval was delayed and the commercial path remains uncertain, efpeglenatide's outcome data cement its place as a significant agent in the GLP-1 class literature.
These are effects reported or investigated in research, much of it preclinical. They are not proven outcomes or health claims.
~3–4 days (GLP-1 analog)
Educational content only. Not medical advice. Consult a licensed physician before use.
Common side effects
Histamine reactions
Possible at the injection site, as with most injected peptides.
Common fixes
Stop and get help
Basis: Limited data; general experience with injected peptides. Educational only, not medical advice.
Insulin and sulfonylureas (glipizide, glyburide, glimepiride)
Higher risk of low blood sugar when combined. Prescribers often lower these doses at the start; check your glucose more often.
Medicines taken by mouth (especially levothyroxine, antibiotics, seizure medicines and warfarin)
Slower stomach emptying can delay or reduce how they're absorbed, most of all after the first dose and each dose increase. Ask your prescriber whether timing or monitoring should change.
Birth control pills
Tirzepatide can make pills less reliable when starting and raising the dose; see Birth control & pregnancy on this card.
Diuretics, ACE inhibitors or ARBs (lisinopril, losartan) and NSAIDs (ibuprofen, naproxen)
Vomiting or diarrhea can dehydrate you and strain the kidneys, a risk these medicines add to. Keep fluids up and call your clinician if you can't keep liquids down.
Planned surgery, sedation or endoscopy
Tell the anesthesia team you take this. Food can stay in the stomach longer, which raises aspiration risk under anesthesia.
Other GLP-1-type medicines (semaglutide, tirzepatide, liraglutide and similar)
Don't stack two drugs from this class; it multiplies side effects without proven benefit.
Everything else you take, including supplements
Bring a full list of medicines and supplements to your pharmacist or clinician before starting.
Basis: FDA prescribing information for GLP-1 medicines (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide); investigational members of the class are assumed to share these until studied. Educational only, not medical advice. Never stop or change a prescribed medicine without your prescriber.
Protocols & tracking are members-only
Members see the research protocols for Efpeglenatide, plan schedules, track every dose and vial, and ask the AI Advisor questions with cited sources. Try every Researcher feature free for 7 days, no card needed.